Salubris released its performance for the first half of the year, with a net profit attributable to the parent company of 365 million yuan, an increase of 6.10%

According to the Zhitong Finance APP, Salubris (002294.SZ) released its semi-annual report for 2025, showing an operating income of 2.131 billion yuan, a year-on-year increase of 4.32%. The net profit attributable to shareholders of the listed company was 365 million yuan, a year-on-year increase of 6.10%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 347 million yuan, a year-on-year increase of 3.93%. The basic earnings per share were 0.33 yuan.

During the reporting period, the sales of patents and new products saw significant growth, greatly enhancing revenue contribution, which has become a core pillar of the company's performance growth. In the field of hypertension, the company has built a differentiated product portfolio that continues to expand, accurately covering the medication needs of different patients, from Xinlitai (ARB class), Xinchao Tuo (ARNI class), to Fuli Tain® (ARB/CCB class compound preparation), and Fuli An® (ARB/diuretic class compound sustained-release preparation)